



Supplemental Figure 1. Influence of TFR1 duration for a successful TRF2.



Supplemental Figure 2. TFR2 duration in patients who switched from imatinib (IM) to Second generation tyrosine kinase inhibitors (2G-TKIs) (n=9) after TFR1 as compare to patients who restarted with IM (n=13). Median TFR2 duration was 0.8 years for IM-IM patients and was not reached for IM-2G-TKIs patients.



Patients at risk	9	7	5	2	2	—
	13	4	2	2	2	- - -